

Express Mail Label No. EV695513715US  
Date of Deposit: February 21, 2007

Attorney Docket No. 22058-519 (GIS268A2)



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT'S: Wynn et al.  
SERIAL NUMBER: 10/671,034 EXAMINER: Fozia Hamud  
FILING DATE: September 25, 2003 ART UNIT: 1647  
FOR: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13 AND IL-13 RECEPTOR CHAINS


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Declaration of Thomas Wynn

I, Thomas Wynn, Ph.D., declare and state:

1. I am a joint inventor of the subject matter described and claimed in United States Patent Application Serial No. 10/671,034, filed September 25, 2003 ("the 034 application"), entitled "Treatment of Fibrosis by Antagonism of IL-13 and IL-13 Receptor Chains".
2. I am a co-author of the publication entitled "IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE Response Induced by *Schistosoma mansoni* eggs," Journal of Immunology 162:920-30, 1999. The publication describes Applicant's own work.
3. Co-authors Monica Chiramonte, Tamlyn Y. Neben, and Debra D. Donaldson are co-inventors on the '034 application. The remaining co-authors, Lisa R. Schopf and Allen W. Cheever, are not co-inventors of the subject matter claimed in the present patent application.

4. I further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that willful false statements may jeopardize the validity of this application and any patent issuing therefrom.



Thomas Wynn

2/15/2007  
Date